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CD4+ eﬀector cells, based on cytokine production, nuclear receptors and signaling pathways, have been categorized into four
subsets. T-helper-1 cells produce IFN-γ,T N F - β, lymphotoxin and IL-10; T-helper-2 cells produce IL-4, IL-5, IL-10, IL-13, IL-
21 and IL-31; T-helper-3, or regulatory T-cells, produce IL-10, TGF-β and IL-35; and the recently discovered T-helper-17 cell
produces IL-17, IL-17A, IL-17F, IL-21, IL-26 and CCL20. By producing IL-17 and other signaling molecules, Th17 contributes to
the pathogenesis of multiple autoimmune diseases including allergic inﬂammation, rheumatoid arthritis, autoimmune gastritis,
inﬂammatory bowel disease, psoriasis and multiple sclerosis. In this article, we review the diﬀerential regulation of inﬂammation
in diﬀerent tissues with a major emphasis on enhancement of neuroinﬂammation by local production of IL-17 in the brain. By
understanding the role of pathogenic factors in the induction of autoimmune diseases by Th17 cells, CAM practitioners will be
able to design CAM therapies targeting Th17 and associated cytokine activities and signaling pathways to repair the intestinal and
blood-brain barriers for their patients with autoimmunities, in particular, those with neuroinﬂammation and neurodegeneration.
1.Introduction
For more than 30 years T-helper (Th) cells have been
divided by immunologists into two functional subsets: T-
helper-1 (Th1) and T-helper-2 (Th2). Th1 and Th2 subsets
are characterized by a distinct activity of transcription
factor and pattern of cytokine-secretion phenotype [1, 2].
This diﬀerentiation of CD4+ T-cells toward Th1, Th2 and
other subsets depends on an appropriate signal through
the TCR and generated cytokine milieu is an important
factor that inﬂuences CD4 cell lineage commitment. For
example, interleukin (IL)-12 activates STAT4 and drives
na¨ ıve CD4+ T cells to become Th1 cells that produce
interferon-gamma (INF-γ). These signals from IL-12 and
IFN-γ by acting through STAT4 and STAT1, increase the
expression of the transcription factor called T-bet, which
promotes further production of IFN-γ and commitment to
the Th1 cell lineage. Th1 cells classically produce IFN-γ,
tumor necrosis factor-beta (TNF-β) and interleukin-10 (IL-
10), and mediate cellular immune responses against tumor
cells, intracellular viruses and bacteria through activation of
macrophages and cytotoxic T-cells. In addition, Th1 cells
drive cell-mediated response leading to tissue damage and
drive humoral immune responses in certain immunoglobu-
lin subclasses termed Ig2a. Innate immune cells, by signals
through STAT6, secrete IL-4 that induces na¨ ıve CD4+ T
cells to become Th2 cells. This leads to the expression
of transcription factor GATA3. This cascade of events in
turn results in the production of IL-4, IL-5, IL-13, IL-21
and IL-31, which are important for host defense against
helminths and contribute to the pathogenesis of asthma
and allergy [3–7]. Another lineage of T-cells that co-express
CD4 and CD25 are Th3 cells, or regulatory T (TREG) cells,
which have the capacity to regulate both Th1 and Th2
cell function, and maintain homeostasis in the immune
system [8, 9]. TREG cells can be developed from thymic
CD4+ T-cell precursors in the presence of IL-2 and TGF-
β, which are termed natural TREG cells. In the periphery,
na¨ ıve CD4+ T cells, by signaling through STAT5 in the
presence of transforming growth factor-beta (TGF-β)c a n
also be converted and become inducible TREG, which express
transcription factor FoxP3. TREG cells produce low levels
of IL-2 and IFN-γ,b u tp r o d u c eh i g hl e v e l so fI L - 1 0 ,I L - 3 5
and TGF-β.T REG cells have an important role in peripheral
self-tolerance and immune suppression. This crucial role
of TREGs in suppressing immune responses to self-antigens2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: General scheme of T-helper cell diﬀerentiation. Naive CD4+ T cells, after activation by T-cell receptor and co-stimulatory
molecules, such as CD28 and inducible T-cell co-stimulator (ICOS), can diﬀerentiate into four eﬀector T-helper cells: Th1, Th2, Th3 or
Th17 cells. These cells produce diﬀerent cytokines, which have specialized immunoregulatory functions. IFN-γ produced by Th1 cells is
important in the regulation of antigen presentation and cellular immunity. IL-4, IL-5 and IL-13 produced by Th2 cells regulate B-cell
responses, important mediators of allergic diseases. TGF-β and IL-10 are produced by Th3 cells to regulate Th1 and Th2 cells. Th17 cells
regulate inﬂammatory responses by expressing IL-17, IL-21, IL-22 and IL-26. CAM protocols can be implemented to reduce the level of
proinﬂammatory cytokine IL-6, thereby inhibiting the conversion of activated T cells into pathogenic Th17 cells.
and in preventing autoimmune disease is done by two
diﬀerent immunoregulatory immunosuppressive or anti-
inﬂammatory cytokines, IL-10 and TGF-β.T h ei m p o r t a n c e
of the TREG in the modulation of the immune system and its
potential for CAM intervention was reviewed by the senior
author earlier in this journal [10–12]. In recent years, a
speciﬁc T-cell subset, termed Th17 cell, with the capacity to
produce a distinct cytokine called IL-17, has been identiﬁed
[13]. Th17 cells develop from na¨ ıve CD4+ T cells in response
to IL-6, IL-23, TGF-β and IL-1β.I L - 6a n dI L - 2 3a c t i v a t e
STAT3, which increases the expression of RORγta n dR O R γ
transcription factors, which in turn promote the expression
of IL-17A, IL-17F, IL-21 and IL-22. Th17 cells are important
for host defense against extracellular bacteria and are
involved in mediating autoimmune diseases [6, 14, 15]. This
subdivision of T-helper cells and their diﬀerentiation from a
na¨ ıve CD4 cell is shown in Figure 1. The immunopathogenic
activities of Th17 cell in inﬂammation and autoimmunity
with possible CAM intervention is discussed in this review
article.
Sincethepastdecadehaswitnessedmanyrevisionsinthe
Th1/Th2 hypothesis and the involvement of Th1/Th2 in T-
cell-mediated tissue damage, it is possible in the future for
manyadditionalcomplexitiesrelatedtoCD4+ T-celldiversity
to become evident in the ﬁeld of human immunology.
Therefore, CAM researchers should be aware that the extent
to which some aspects of T-cell subsets in humans are ﬁrmly
ﬁxed while others may change will continue to be the subject
of intense investigation and future reports.
2.Immunopathogenicity ofTh17 Cells
The role of Th17 lymphocytes in immunopathogenic pro-
cesses has recently been formally established. T-cells produc-
ing IL-17 constitute a new lineage of CD4+ T-cells developed
directlyfromna¨ ıveCD4T-cells,whichseemstoplaykeyroles
intheactivationofneutrophilsandtheimmunitytobacteria,
particularly at mucosal surfaces. The Th17 cell has also
been linked to a growing list of cancers, autoimmune and
inﬂammatory diseases such as rheumatoid arthritis, systemic
lupus erythematosus, multiple sclerosis, asthma, psoriasis,
systemic sclerosis, chronic inﬂammatory bowel disease and
allograft rejection [6, 13–20].
Although the importance of IL-17-producing CD4+ T
cells in the pathogenesis of autoimmune diseases is widely
accepted, the signaling pathway involved in the development
and maintenance of these cells only recently became clear
[21–23]. In this model, interleukin-23 (IL-23) plays a
signiﬁcant role in the development of Th17 cells. Th1 and
Th2 eﬀector molecules antagonize the development of Th17
cells, which are responsible for destructive tissue pathology
in autoimmune diseases including neuroinﬂammation [24–
26]. Whereas, na¨ ıve CD4 cells in the presence of IL-12 and
transcription factors, such as T-bet and STAT4, become Th1
cells, which express IL-12R and produce IFN-γ.H o w e v e r ,
na¨ ıve CD4 cells in the presence of IL-4, GATA-3 and STAT6
become Th2 cells, which produce IL-4. Finally, naive CD4
cells in the presence of TGF-β, IL-23 and transcription factor
RORγt become IL-17-producing Th17 cells.Evidence-Based Complementary and Alternative Medicine 3
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Figure 2: Cytokine production by dendritic cells and macrophages induce development of TReg, Th17 or IL-17-producing cells from naive
CD4 cells and regulation of Th17 cells by Th1 and Th2 cytokines.
Playing on its pathogenic role, IL-17 produces an
inﬂammatory cascade. IL-17 activates ﬁbroblasts to pro-
duce proinﬂammatory cytokines such as TNF-α,I L - 1 β and
IL-6, resulting in tissue inﬂammation and autoimmunity
(Figure 2). From this ﬁgure it is possible to conclude that
the level of immunoregulatory cytokine TGF-β is crucial for
diﬀerentiation of Th17 cells. For CAM practitioners, these
ﬁndings strongly suggest that targeting signature cytokine
expression by Th1 or Th2 cells, in addition to targeting
Th17 cells and their associated cytokines and transcription
factors, directly or indirectly, may be more eﬃcacious for
the treatment of inﬂammatory and autoimmune disorders
including neuroinﬂammation and neuroautoimmunity.
3.Th17 Development RequiresTGF-β withIL-6
Recent studies demonstrate that the development of the
human Th17 cell requires TGF-β and one or more proin-
ﬂammatory cytokines such as IL-6 [27, 28]. Data generated
in one study have shown that for Th17 development den-
dritic cells stimulated with β-glucan or zymosan, TGF-β and
IL-6 were partially required, but the necessity for IL-1 was
absolute [29, 30]. However, a diﬀerent study in which na¨ ıve
human CD4+ T cells were isolated from cord blood revealed
thatTGF-βplaysacriticalroleinhumanTh17diﬀerentiation
[31]. In these and other studies it has been reported that
very low concentrations of TGF-β such as 25pg/mL, will
give rise to Th17 cells, and high concentrations of TGF-
β (2ng/mL or more) will begin to favor production of
regulatory T cells (CD4+ and CD25+), with or without
the presence of IL-6 [32–41]. It could be concluded that
regulation of T-helper cell diﬀerentiation can occur via
coordinated activities of cytokines and transcription factors
(see Figure 2). It seems that TGF-β produced by dendritic
cells and macrophages can regulate both the diﬀerentiation
to TREGs and IL-17-producing Th17 cells. Therefore, TGF-
β induces co-expression of transcription factors FoxP3
and RORγt, which are important for diﬀerentiation of
TREG or Th17 cells, respectively. High concentrations of
TGF-β (2ng or greater) force the co-expression of FoxP3,
which blocks RORγt-dependent gene expression, resulting
in na¨ ıve CD4+ cell diﬀerentiation to TREG cells. However,
low concentrations of TGF-β (25pg/mL or less) along with
one of these proinﬂammatory cytokines, IL-6, IL-21, IL-23
or IL-1, induce the expression of RORγt resulting in the
diﬀerentiation to Th17 positive cells and thus, the expression
of IL-17 [7, 31, 32]. It seems that FoxP3 antagonizes RORγt
via physical interaction, while inﬂammatory mediators, such
as IL-6 and IL-21, relieve this inhibition possibly by a post-
translational eﬀect on either RORγto rF o x P 3[ 32, 42, 43].
4. Th17 Lymphocyte-MediatedAllergic
Inﬂammation
It is accepted that CD4 T-helper lymphocytes are essential
regulators of immune responses and inﬂammatory diseases
[44]. Th2 cells mediate humoral immunity and allergic
responses. In addition to Th2, Th17 cells and IL-17 have
been implicated in allergic inﬂammation. This novel IL-17
cytokine family also mediates the migration and activation
of inﬂammatory cells in the airways, resulting in inﬂam-
mation that is typical in asthma [45, 46]. IL-17 has also
been associated with many inﬂammatory and autoimmune
diseases [47–49]. Recently, it was shown that IL-6 could
regulate Th17 development in both mice and humans [50–
52]. Therefore, it is not surprising that both Th2 and Th174 Evidence-Based Complementary and Alternative Medicine
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Figure 3:EﬀectsofbacterialtoxinsandallergensondendriticcellactivationofcAMPinductionoftransmembranesignalinganditsreceptor
ligand. Binding of c-Kit to its ligand SCF stimulates dendritic cells to secrete IL-6. IL-6 acts as a key factor in diﬀerentiation of T lymphocytes
intoTh2 andTh17 cells, which contribute tothe development of allergic andautoimmune diseases. Byinhibiting enhanced IL-6production,
CAM practitioners may prevent, slow down or reverse the development of allergic and inﬂammatory disorders.
responses are elicited by diﬀerent allergens in asthma [46].
In these conditions, IL-6 produced by dendritic cells (DCs)
acts as a control regulator by not only promoting Th2
and Th17 responses, but also in limiting the Th1 response
[50–52].
By producing IL-6, DCs are integral to diﬀerentiation of
T-helper into Th2 and Th17 subsets. However, molecular
mechanisms that regulate IL-6 production by DCs have
not been elucidated. To identify a previously unknown
signaling axis in DCs that inhibits Th1 immune response,
but promotes the induction of Th2 and Th17 responses,
experiments were performed using bacterial toxins and
house dust mite (HDM) in both in vitro and in vivo
systems [53]. Krishnamoorthy and colleagues [53] examined
the multi-cellular pathway in which HDM (allergen) acts
on dendritic cells to drive na¨ ıve CD4 cells to Th2 and
Th17 cell diﬀerentiation. To clarify these molecular steps
linking allergens’ immunization to diﬀerentiation of T cells,
they initially approached this problem by using microarray
expression to identify genes induced by bacterial toxins and
HDM. The authors incubated DCs either with cholera toxin
orwithHDM,theexperimentalallergen.Bothbacterialtoxin
and HDM induced IL-6 secretion along with cell surface
expression of C-KIT and its ligand, stem cell factor (SCF),
on DCs, blocking IL-6 by monoclonal antibody prevented
induction of both Th2 and Th17 cells. They also showed that
this dual upregulation of C-KIT and SCF results in sustained
signaling downstream of C-KIT, inducing IL-6 secretion.
To show that both C-KIT and SCF are required for induction
of IL-6 and activation of Th2 and Th17 cells, the researchers
employed dendritic cells expressing mutants for C-KIT and
SCF and cultured them with cholera toxin. Dendritic cells
with compromised cell surface expression secreted less IL-6
[53].
The work of Krishnamoorthy and colleagues [53] shows
that both bacterial toxins and allergens induce cell surface
expression of C-KIT and its ligand SCF. The binding of
C-KIT to its ligand activates PI3-kinase signaling, which
stimulates the production of IL-6. Secreted IL-6 ultimately
contributes to the induction of Th2 and Th17 cells, resulting
in allergies and some autoimmune diseases (Figure 3). These
ﬁndings suggest that the blocking of C-KIT binding to
its ligand or inhibiting the production of IL-6 could be
therapeutically useful for the treatment of allergic and
autoimmune diseases. This approach is likely to stimulate
further studies by CAM practitioners that could uncover
additional targets for intervention in allergic and autoim-
mune diseases.
5. Contribution of Th17 Lymphocytes to
Autoimmune Disorders
Immunocompetent cells in particular CD4+ T-lymphocytes
are involved in the pathogenesis of chronic inﬂammatoryEvidence-Based Complementary and Alternative Medicine 5
disease by the production of unique sets of cytokines and cell
surface molecules [54]. The activity of IFN-γ-producing Th1
lymphocytes has traditionally been linked to the induction
and progression of tissue damage in Psoriasis volgaris,
Crohn’sdisease,rheumatoidarthritisandotherautoimmune
diseases. Therefore, these diseases have been classiﬁed as
Th1-associated disorders [5].
Recently, however, a novel subpopulation of memory
CD4+ T-lymphocytes has been identiﬁed that produces high
levels of IL-17, which plays a major role in the induction of
inﬂammation and tissue destruction in various autoimmune
disorders [55–60]. In addition, IL-17 is produced by γδ T
cells, which are involved in collagen-induced arthritis (CIA)
[61]. The depletion of γδ T cells during CIA results in
less severe diseases, indicating a pathogenic role of these
IL-17-producing cells [61]. IL-17 and its relatives IL-17A
and IL-17F have very strong proinﬂammatory eﬀects on
many cellular targets, including ﬁbroblasts, epithelial cells,
endothelialcells,monocytes/macrophages,keratinocytesand
osteoclasts [62]. To conﬁrm the involvement of Th17 in
inﬂammatory lesions, Pene and colleagues [62] isolated
up to 30% of inﬁltrating lymphocytes from inﬂammatory
lesions. These activated Th17 cells produced IL-26, TNF-
α, lymphotoxin-B and IL-22. Produced at relatively high
concentrations, these cytokines were inversely correlated
with the production of Th1 and Th2 cytokines [63].
Results showed that tissue-inﬁltrating Th17 cells con-
tributesigniﬁcantlytohumanchronicinﬂammatorydiseases
through the production of inﬂammatory cytokines and
create an environment that contributes to inﬂammatory
diseases.
To support the pathogenic role of Th1, Th2 and Th17
in autoimmune diseases, Stummvoll and colleagues [64]
compared the results of adoptively transferred Th1, Th2
and Th17 eﬀector cells in the animal model of autoimmune
gastritis induced by ATPase from gastric parietal cells as
the target antigen. They found that while each injection
of Th1, Th2 and Th17 cells induced gastritis, the transfer
of Th17 eﬀector cells caused the most dramatic pathology.
At 4 weeks of cell injection, 20% of Th1 recipient, 60%
of the Th2 recipient and 80% of Th17 recipient animals
showed evidence of autoimmune gastritis. Interestingly, co-
transfer of regulatory T cells (IL-10 and TGF-β secreting)
was capable of reducing the incidence and severity of
this autoimmune disease in Th1 and Th2 injected mice,
but not in the Th17 injected group. Taken together, this
strong inhibitory eﬀect of TREG on Th1 and Th2 eﬀector
cells makes TREG an attractive CAM therapeutic target for
some autoimmune diseases. However, if the autoimmune
disease is caused by Th17 cells, it should then become
an additional target for CAM treatment. This diﬀeren-
tiation between Th1 and Th17 induction of autoimmu-
nity requires laboratory measurement of these cytokines.
Therefore, in assessing patients with autoimmune disorders,
the measurement of Th1 (IFN-γ), Th2 (IL-4, IL-5, IL-
13) and Th17 (IL-17) cytokine production by cultured
lymphocytes will guide CAM practitioners in tailoring
propertreatmentsforTh1-andTh17-mediatedautoimmune
diseases.
6. Induction of Central NervousSystem
Autoimmunity by Th17
IL-17-producing T-helper cells play an important role in
the induction of autoimmune diseases, including multiple
sclerosis and its animal model called experimental autoim-
mune encephalomyelitis (EAE) [65, 66]. This observation
is based on the detection of IL-17 levels in both the
plaques and cerebrospinal ﬂuid of MS patients [67–69].
In the previous section, it was established that IL-17 is a
proinﬂammatory cytokine that stimulates epithelial, ﬁbrob-
last and endothelial cells to produce other inﬂammatory
chemokines and cytokines, including macrophage inﬂam-
matory protein (MIP)-2, monocyte chemoattractant protein
(MCP-1), granulocyte-colony stimulating factor (G-CSF)
and IL-6 [47–49]. Interestingly, IL-17 synergizes with two
inﬂammatory cytokines, IL-1β and TNF-α, to further induce
chemokine expression [70, 71]. Since it is well known that
microglia function as antigen presenting cells and eﬀector
cells and are involved in the inﬂammatory demyelination
of the central nervous system (CNS), researchers examined
the eﬀect of IL-17 produced by Th17 cells on microglia in
order to examine the contribution of IL-17 to inﬂammatory
demyelination in the CNS. It was shown that treatment of
microglia with IL-17 upregulated microglia production of
IL-6, MIP-2, nitric oxide, neurotrophic factors and adhesion
molecules. Also, when IL-1β a n dI L - 2 3w e r ea d d e dt o
microglia, a signiﬁcant amount of IL-17 was produced [72].
Microglia produce IL-1β and IL-23 under inﬂammatory
conditions. These cytokines may act in an autocrine manner
to further induce IL-17 expression in microglia, and thereby
contribute to neuroimmune diseases, such as MS, in the
central nervous system [72]. To further support the IL-
17 association with neuroimmune disorders, mice injected
with speciﬁc antibodies against IL-17 resulted in inhibition
of chemokine expression, whereas overexpression of IL-17
in lung epithelia resulted in chemokine production and
leukocyte inﬁltration. Thus, IL-17 expression characterizes
a unique T-helper lineage, distinct from Th1 and Th2 cells,
that plays a signiﬁcant role in tissue inﬂammation [73].
In MS, the location of lesions in the CNS is variable
and is a very important determinant of clinical outcome.
This diﬀerence in lesion distribution, which is linked to
HLA complex, suggests that T-cell speciﬁcity inﬂuences the
sites of inﬂammation. Based on this observation, in a recent
study it was demonstrated that T-cells speciﬁc to MBP
epitopes generate two diﬀerent populations of helper cells,
Th17 and Th1 [74]. Notably, the Th17 to Th1 ratio of
inﬁltrating T-cells determines whether or not inﬂammation
occurs in the CNS. It was concluded that inﬂammation in
the brain parenchyma occurs when the ratio of Th17 to
Th1 is much greater than one. This outnumbering of Th1
by Th17 cells triggers a disproportionate increase in IL-
17 in the brain resulting in inﬂammation. Consistent with
the clinical phenotype, neutralization of IL-17 eliminated
parenchymal inﬂammation in the brain [74]. Altogether,
this study indicates that Th17, Th1 and their ratio, along
with inﬂammatory cytokines, chemokines and adhesion
molecules, are the mechanisms regulating cell inﬁltration6 Evidence-Based Complementary and Alternative Medicine
into the brain parenchyma. Furthermore, the established
diﬀerential regulation of inﬂammation in the brain with
aT h 1 7 : T h 1r a t i o>1, while in the spinal cord with a
Th17:Th1 ratio <1, indicates that Th1 cells play a signiﬁcant
pathologic role in spinal cord autoimmunity [74]. It was
concluded that IL-17 produced by Th17 cells is the major
regulator of central nervous system autoimmunity.
Production of IL-17 induces the activation of matrix
metalloproteinase-3 (MMP-3) and recruits neutrophils to
the site of inﬂammation. Neutrophil activation of enzymes
such as MMPs, proteases and gelatinases, contributes to
blood-brain barrier (BBB) breakdown. BBB breakdown fur-
ther enhances the recruitment of neutrophils. This increase
in protease activity, which attracts a signiﬁcant number
of monocytes and macrophages to the inﬂammatory sites,
leads to sustained myelin and axonal damage [73, 75–77].
Together, these ﬁndings imply that CAM therapies, which
may include medication, immune response modiﬁers or
herbal medicine, that target IL-17 activity may be the most
beneﬁcial for patients with autoimmunities and neuroau-
toimmunities, particularly for patients with lesions in the
brain.
7. Conclusion
On the basis of signature cytokine expression, transcription
factorsandsignalingpathways,eﬀectorT-helpercellsinclude
Th1, Th2, Th3 and Th17. The latest T-helper to be deﬁned,
Th17, together with its cytokine family of IL-17, has been
deemedthemostpathogenicininﬂammatoryneuroimmune
and autoimmune disorders. An activated T-cell, triggered
by TGF-β in the presence of IL-6, diﬀerentiates to Th17.
Subsequently, this T-helper then produces eﬀector cytokines
IL-17, IL-17A, IL-21, IL-22 and IL-26. This cytokine family
is involved in inducing and mediating proinﬂammatory
responses. Speciﬁcally, IL-17 mediates the migration and
activation of inﬂammatory cells in the airways, resulting
in the inﬂammation often seen in asthma, and is com-
monly associated with an allergic inﬂammatory response.
Tissue-inﬁltrating Th17 cells contribute signiﬁcantly to
chronic inﬂammatory diseases. Inﬂammation in various
tissues is achieved by secreted IL-17 and its relatives IL-
17A and IL-17F due to their proinﬂammatory eﬀects on
cellular targets, which include endothelial cells, epithelial
cells,ﬁbroblasts,keratinocytes,monocytes/macrophagesand
osteoclasts. Under CNS inﬂammatory conditions, microglia,
which act as antigen presenting cells, produce IL-1β and
IL-23. Acting in an autocrine manner, these cytokines may
further induce IL-17 expression in microglia, contributing
to neuroimmune disorders. Another inﬂammatory pathway
involving IL-17 is the IL-17-induced activation of MMP-
3, which recruits neutrophils to the site of inﬂammation.
Neutrophils then activate proteases and gelatinases, which
contribute to an enhanced BBB permeability, and even-
tual myelin and axonal damage. Indeed, Th17 and IL-
17 have far-reaching inﬂammatory properties. Thus, any
patient who presents with autoimmune, inﬂammatory, or
neuroimmune symptomatology would greatly beneﬁt from
an individualized treatment protocol. CAM practitioners
may implement personalized therapies for these patients
by measuring vital cytokine production that included IFN-
γ (Th1), IL-4, IL-5 and IL-13 (Th2), and IL-17 (Th17).
The modulation of IL-17, IL-6, NF-κB and other factors
may be useful therapeutic targets to CAM practitioners
who tailor appropriate therapies for their patients exhibiting
neuroimmune disorders. As with any research model, this
work on CD4+ T-cell diversity in human diseases is a work in
progress and is subject to enhancement in the coming years.
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